Redsenol
{{Article for deletion/dated|page=Redsenol|timestamp=20250510235934|year=2025|month=May|day=10|substed=yes|help=off}}
{{Medical citations needed|date=May 2025}}
{{Infobox product
| title = Redsenol
| type = Ginsenoside
| inventor =
| manufacturer = Canada Royal Enoch Phytomedicine
| available = Yes
| url = https://enophyto.com/
}}
Redsenol is a ginsenoside supplement which is developed by Canada Royal Enoch Phytomedicine, a pharmaceutical company headquartered in British Columbia, Canada that researches and develops ginsenosides.{{Cite web |last=|date=2025-03-13 |title=Ginsenoside Supplement Redsenol-1 Plus Gains Recognition in National Cancer Institute's Drug Dictionary |url=https://www.citybuzz.co/2025/03/13/ginsenoside-supplement-redsenol-1-plus-gains-recognition-in-national-cancer-institutes-drug-dictionary/ |website=citybuzz |language=en-US}}{{Cite news |title=Ginsenoside Supplement Redsenol-1 Plus Included in National Cancer Institute's Drug Dictionary |url=https://finance.yahoo.com/news/ginsenoside-supplement-redsenol-1-plus-110000367.html |work=finance.yahoo.com}}{{Cite press release |last=Ltd |first=Canada Royal Enoch Phytomedicine |title=Canada Royal Enoch Phytomedicine Launches Clinical Trial of its Ginseng-Derived Redsenol-1 Plus Noble Ginsenoside Capsules |url=https://www.prnewswire.com/news-releases/canada-royal-enoch-phytomedicine-launches-clinical-trial-of-its-ginseng-derived-redsenol-1-plus-noble-ginsenoside-capsules-301720005.html |website=www.prnewswire.com |language=en}}{{cite web |title=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ginsenosides-supplement |url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ginsenosides-supplement |website=www.cancer.gov |access-date=9 May 2025 |language=en |date=2 February 2011}}
In 2018, Redsenol Ginsenosides was certified by the Banned Substances Control Group (BSCG) under its BSCG Certified Drug Free® program.{{cite web |title=Redsenol Takes a Big Step Forward Toward the Best Ginsenoside Brand |url=https://markets.financialcontent.com/stocks/news/read/37277113/redsenol_takes_a_big_step_forward_toward_the_best_ginsenoside_brand |website=markets.financialcontent.com}}
In March 2025, Redsenol-1 Plus Noble Ginsenosides has been included in the National Cancer Institute's (NCI) Drug Dictionary.{{cite web |last1=Magazine |first1=I. H. R. |title=Redsenol-1 Plus Listed in NCI Drug Dictionary |url=https://ihrmagazine.com/redsenol-1-plus-nci-drug-dictionary-recognition/ |website=IHR Magazine |date=17 March 2025}}{{Cite web |title=Come For Health, fully experience good health by providing the finest supplements, foods, and lifestyle solution. |url=https://www.comeforhealth.ca/product/redsenol-1-noble-ginsenoside-capsules-contain-16-rare-ginsenosides-3-boxes-x-90-capsules |website=ComeForHealth |language=en}}
Currently, Redsenol-1 Plus is undergoing a clinical trial to evaluate its efficacy in reducing cancer-related fatigue, which began in 2022.{{cite web |title=A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults |url=https://clinicaltrials.gov/study/NCT05664009 |publisher=clinicaltrials.gov |date=3 April 2024}}